-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 11, Hongri Pharmaceutical announced that the company's drug fasudil hydrochloride injection passed the quality and efficacy consistency evaluation of generic drugs.
It is understood that fasudil hydrochloride injection and developed by Asahi Kasei and Nagoya University, respectively, in 1995 and launched in Japan in 2001 and listed in China, mainly for Cerebral Vascular spasm spasms caused by the Improvement of symptoms of ischemic cerebrovascular disease.
Listed in 1995 and 2001 in China listed in Japan, mainly for Cerebral Vascular spasm improve symptoms of ischemic cerebrovascular disease caused by the twin.
In the acute phase of cerebral thrombosis (within 48 hours after the onset).
According to "China subarachnoid hemorrhage treatment guidelines 2019", subarachnoid hemorrhage (SAH) refers to the kind of brain after brain or the bottom surface of the brain blood vessels rupture, causing blood into the subarachnoid space corresponding clinical symptoms of stroke, accounting for all 5% to 10% of strokes.
